Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis
- 1 May 1991
- journal article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 40 (5) , 473-476
- https://doi.org/10.1007/bf00315225
Abstract
The effects of ursodeoxycholic acid (UDCA, 450 mg daily) in patients with histologically proven chronic active hepatitis (CAH) have been evaluated in a randomized, double-blind, placebo-controlled study. Twenty-six patients with serum alanine aminotransferase (ALT) values at least twice the normal upper limit in two of three pre-treatment tests received UDCA or a placebo for twelve weeks.Keywords
This publication has 16 references indexed in Scilit:
- Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trialGastroenterology, 1989
- IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?The Lancet, 1987
- Anti-cholestatic and cytoprotective properties of ursodeoxycholic acid. Studies in vivo and vitro.Kanzo, 1987
- Gallbladder emptying response to sham feeding in humansGastroenterology, 1986
- Effect of chenodeoxycholic and ursodeoxycholic acids on isolated adult human hepatocytesDigestive Diseases and Sciences, 1984
- Medical Treatment of Cholesterol Gallstones by Bile Desaturating AgentsHepatology, 1984
- Influence of Hydroxylation and Conjugation of Bile Salts on Their Membrane-Damaging Properties-Studies on Isolated Hepatocytes and Lipid Membrane Vesicles†Hepatology, 1984
- Safe Use of Ursodeoxycholic Acid in the Treatment of Dyspeptic Symptoms in Patients with Chronic Active Hepatitis: A Double-Blind Controlled TrialJournal of International Medical Research, 1982
- Erfahrungen bei der Behandlung von Gallensteinpatienten mit ChenodesoxycholsäureDeutsche Medizinische Wochenschrift (1946), 1977
- Dissolution of Cholesterol Gallstones by Chenodeoxycholic AcidNew England Journal of Medicine, 1972